Multi-engine growth delivered in H1 2026, with recurring revenue up 18% YoY and strong cash reserves. Strategic advances in dermatology, GI pipeline, and MedTech AI support reaffirmed double-digit growth guidance for FY2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.